Back to results
US 2026/0308518 A1Published application
Metabolically enhanced vd1 t cells and uses thereof
OwnerLydia Lynch, Cathal Harmoninventors
Life of this patent
Estimating the term…
Abstract
Described herein are Vδ1 T cells that are cytotoxic in nature and exhibit improved metabolic activity. Also described here are methods for expansion of such Vδ1 T cells. Further provided are use of such Vδ1 T cells in methods of treatment.
Claims31
A method for expansion of a population of γδ T cells of Vδ1 subtype (Vδ1 T cells), the method comprising:
- (i) providing a population of cells comprising Vδ1 T cells isolated from a human subject;
- (ii) culturing the Vδ1 T cells from step (i) in a first medium comprising human serum, interleukin 1β (IL-1β), IL-4, IL-21, interferon gamma (IFNγ), and an anti-CD3 antibody or an antigen-binding fragment thereof, for 10-20 days, optionally wherein the first medium further comprises glutamine;
- and
- (iii) culturing the cells in a second medium comprising human serum, IL-15, IFNγ, IL18, an anti-CD2 antibody or an antigen-binding fragment thereof, and an anti-CD3 antibody or an antigen-binding fragment thereof, for 3-10 days, optionally wherein the second medium further comprises glutamine.
1 more element
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-27. (canceled)
-30. (canceled)
(canceled)
Dependencies are inferred from the claim text.